CD274 and neoplasm: Further preclinical studies are warranted to evaluate the expansion of novel circulating tumor cell (CTC) signatures to predict treatment efficacy in response to possible sorafenib or ATRA + romidepsin chemotherapy combined with anti‐PD‐L1 immunotherapy in a PDX model.